Nanocarrier-based drug combination therapy for glioblastoma

The current achievements in treating glioblastoma (GBM) patients are not sufficient because many challenges exist, such as tumor heterogeneity, the blood brain barrier, glioma stem cells, drug efflux pumps and DNA damage repair mechanisms. Drug combination therapies have shown increasing benefits ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Mengnan, van Straten, Demian, Broekman, Marike L.D., Préat, Véronique, Schiffelers, Raymond M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956816/
https://www.ncbi.nlm.nih.gov/pubmed/31938069
http://dx.doi.org/10.7150/thno.38147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956816/
https://www.ncbi.nlm.nih.gov/pubmed/31938069
http://dx.doi.org/10.7150/thno.38147

Ejemplares similares